Publication

Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer

Journal Paper/Review - May 23, 2014

Units
PubMed
Doi

Citation
Blum D, Rosa D, deWolf-Linder S, Hayoz S, Ribi K, Koeberle D, Strasser F. Development and validation of a medical chart review checklist for symptom management performance of oncologists in the routine care of patients with advanced cancer. J Pain Symptom Manage 2014; 48:1160-7.
Type
Journal Paper/Review (English)
Journal
J Pain Symptom Manage 2014; 48
Publication Date
May 23, 2014
Issn Electronic
1873-6513
Pages
1160-7
Brief description/objective

CONTEXT
Oncologists perform a range of pharmacological and nonpharmacological interventions to manage the symptoms of outpatients with advanced cancer.

OBJECTIVES
The aim of this study was to develop and test a symptom management performance checklist (SyMPeC) to review medical charts.

METHODS
First, the content of the checklist was determined by consensus of an interprofessional team. The SyMPeC was tested using the data set of the SAKK 96/06 E-MOSAIC (Electronical Monitoring of Symptoms and Syndromes Associated with Cancer) trial, which included six consecutive visits from 247 patients. In a test data set (half of the data) of medical charts, two people extracted and quantified the definitions of the parameters (content validity). To assess the inter-rater reliability, three independent researchers used the SyMPeC on a random sample (10% of the test data set), and Fleiss's kappa was calculated. To test external validity, the interventions retrieved by the SyMPeC chart review were compared with nurse-led assessment of patient-perceived oncologists' palliative interventions.

RESULTS
Five categories of symptoms were included: pain, fatigue, anorexia/nausea, dyspnea, and depression/anxiety. Interventions were categorized as symptom specific or symptom unspecific. In the test data set of 123 patients, 402 unspecific and 299 symptom-specific pharmacological interventions were detected. Nonpharmacological interventions (n = 242) were mostly symptom unspecific. Fleiss's kappa for symptom and intervention detections was K = 0.7 and K = 0.86, respectively. In 1003 of 1167 visits (86%), there was a match between SyMPeC and nurse-led assessment. Seventy-nine percent (195 of 247) of patients had no or one mismatch.

CONCLUSION
Chart review by SyMPeC seems reliable to detect symptom management interventions by oncologists in outpatient clinics. Nonpharmacological interventions were less symptom specific. A template for documentation is needed for standardization.